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ABSTRACT
The timing of surgical resection of synchronous
liver metastases from colorectal cancer has been
debated for decades. Several strategies have
been proposed, but high-level evidence remains
scarce. Simultaneous resection of the primary
tumour and liver metastases has been described
in numerous retrospective audits and meta-
analyses. The potential benefits of simultaneous
resections are the eradication of the tumour
burden in one procedure, overall shorter pro-
cedure time, reduced hospital stay with the
likely benefits on quality of life and an expected
reduction in the use of health care services
compared to staged procedures. However, con-
cerns about accumulating complications and
oncological outcomes remain and the optimal
selection criteria for whom simultaneous resec-
tions are beneficial remains undetermined.
Based on the current level of evidence, simul-
taneous resection should be restricted to
patients with a limited liver tumour burden.
More high-level evidence studies are needed to
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evaluate the quality of life, complication bur-
den, oncological outcomes, as well as overall
health care implications for simultaneous
resections.
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resection; Surgical oncology; Surgical
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Key Summary Points
High-level evidence in simultaneous
resection of colorectal cancer and
colorectal liver metastasis remains scarce.
Simultaneous resections may be
considered in patients with good
performance status and limited liver
tumour burden.
Simultaneous resections should be
avoided when requiring major liver
resection and major colorectal resection.
Treatment strategies should be made by a
multidisciplinary team.
Simultaneous resections should be
performed as part of a clinical trial.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article, go to https://doi.org/10.6084/
m9.figshare.14170694.
INTRODUCTION
The optimal timing of surgical resection of
synchronous liver metastases from colorectal
cancer is not well defined. Traditionally, resec-
tion of the primary tumour and the liver
metastases is done at separate admissions, with
a period of recovery allowed between the two
procedures. This could be done either as resec-
tion of the liver metastases before the colorectal
tumour or in the reversed order. Simultaneous
resection of both the colorectal cancer and the
liver metastases has gained popularity due to
several appealing factors. The tumour burden
can be eradicated in one procedure, which
intuitively could have a positive impact on
quality of life. One versus two procedures is
likely to reduce the overall burden on health
care institutions and lower hospital costs with a
reduced admission rate. However, an increase in
overall and procedure-specific post-operative
morbidity after simultaneous resection have
been reported [1, 2]. Conversely, the traditional
approach with staged resections may also be
argued. An interval between the resection of the
primary tumour and the resection of the liver
metastases allows a test of time to evaluate the
individual tumour biology of the metastatic
disease. The consequence of a staged procedure
might be progression of the liver metastases to
such an extent that they are no longer consid-
ered resectable. While tumour progression in
the perioperative ‘‘window’’ between the two
procedures may be unfavourable, it may spare
the patient of a potentially futile liver resection
that would otherwise have had a limited effect
on cancer biology and the long-term survival.
There is currently a lack of high-level evi-
dence to accurately determine the role of
simultaneous resection of colorectal cancer
with liver metastases. Previous reports are gen-
erally biased by the fact that patients selected to
simultaneous versus non-simultaneous surgery
differ in many aspects concerning both the
primary tumour and the manifestation of the
liver metastases. Furthermore, recent investiga-
tions reveal considerable differences in the
perioperative management of synchronous col-
orectal liver metastases, with no clear surgical
outcome or survival advantage towards any
approach, being liver-first, colorectal-first or
simultaneous resection [3, 4]. This invited
opinion article aims to address the current level
of evidence concerning simultaneous resection
of primary colorectal cancer and synchronous
liver metastases. We propose selection criteria,
based on available data, for whom a
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simultaneous procedure is likely to be benefi-
cial. This article is based on previously con-
ducted studies and does not contain any new
studies with human participants or animals
performed by any of the authors.
CURRENT EVIDENCE
Throughout the last two decades, numerous
retrospective studies have compared simulta-
neous versus staged resection for synchronous
colorectal liver metastases. The findings have
been reported in several reviews and meta-
analyses (Table 1) [3, 5–10]. However, the results
are somewhat difficult to interpret due to
inherent selection bias [11]. Generally, the
outcomes from these studies show equal short-
and long-term results between simultaneous
and staged approaches, besides shorter hospital
stay for patients with simultaneous resec-
tion. Patients with bilobar liver metastases and
in need for major hepatectomy have tradition-
ally been scheduled for staged surgery. Also,
most of the register-based studies do not
account for patients with an initial intent for a
staged strategy, but in whom a proportion of
patients never reached hepatectomy due to
disease progression. Indeed, some studies report
that between 16 and 35% of patients with an
either liver-first or primary tumour-first strategy
do not reach the second operation, likely due to
disease progression or complications from the
first procedure [12–14]. Hence, in the above-
mentioned systematic reviews and meta-analy-
sis, there is an inherent selection bias in favour
of patients completing a staged approach, as
they likely harbour a favourable tumour biology
in order to reach the second procedure. Also, for
patients receiving a simultaneous resection,
there is a selection bias in favour of a limited
liver tumour burden.
A recent population-based cohort study
confirmed an increased tendency towards
simultaneous resection and a wide variation in
surgical approach according to hospital trust of
diagnosis in the UK [4]. Survival analysis on
propensity score-matched groups showed no
difference in 4-year survival between the pri-
mary tumour-first and simultaneous cohort.
Interestingly, the presence of a hepatobiliary
surgical team on site appeared to have an
impact on decision-making, as patients diag-
nosed at hospital trusts with such service were
more likely to undergo a simultaneous or liver-
first approach.
Recently, a randomized controlled trial
addressed the question of whether synchronous
colorectal liver metastases should be resected
simultaneously with the primary cancer or
delayed [15]. There are several interesting find-
ings and lessons to be learned from this trial.
First, there was no difference in major compli-
cations comparing synchronous to delayed
resection. Second, although 10 centres were
involved in the study, the overall recruitment
time was a decade. Even this was not enough to
reach the calculated sample size (estimated 222
patients), in spite of rather broad inclusion cri-
teria, accepting major hepatectomy, patients
with bilobar liver metastases and patients with
rectal cancer. According to the authors, this was
mainly explained by the fact that (i) colorectal
cancer with initially resectable synchronous
liver metastases remains a rare situation, (ii)
centres involved in the study often had patients
referred with poor overall status and initially
non-resectable synchronous liver metastases
and (iii) the majority of patients were referred
after the primary tumour had been resected.
The first point is debatable, as data for colorectal
liver metastases reflect a highly divergent atti-
tude among surgeons towards what is consid-
ered ‘resectable’ disease [16]. Furthermore,
novel techniques have been developed in order
to increase resectability [17]. The latter two
points reflect challenges in logistical and hos-
pital organizational structure rather than the
lack of patients eligible for the procedures. Not
all colorectal units have hepatobiliary surgeons
available and vice versa, which should be taken
into account when planning for simultaneous
resection. Hence, this also reflects the third
point, that referral between pure colorectal
units and hepatobiliary units is required if
patients are not discussed at the same multi-
disciplinary team (MDT) meeting. Even at
institutions with both services available, most
MDTs are run separately, thus representing a
barrier in planning simultaneous resection if
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the surgeons are biased towards one strategy
over another. Of note, payer systems vary across
health care providers, and the financial incen-
tives for any approach (primary first, liver first
or simultaneous) have an impact on decisions
in some countries where billing for service is
implied.
The overall complication rate in this solitary
RCT on the subject, mirrors the inclusion cri-
teria, in that almost 1 out of 2 patients in both
groups had a complication grade III or IV
according to the Clavien-Dindo classification
[15]. Again, a reduction of hospital stay was
proven for patients with simultaneous surgery.
Survival analysis was not conducted according
to intention-to-treat principles. As the trial was
underpowered to answer the primary outcome




As there is evidence of a negative impact from
post-operative complications on long-term
outcomes after liver surgery for colorectal liver
metastases, the magnitude of surgical resection
should be better stratified to guide patient
management decisions [18, 19]. Feasibility
reports on major hepatectomy with concomi-
tant colectomy exist, but this procedure is likely
to be reserved for highly selected patients and
experienced surgeons [20]. In 2015, a consensus
statement was published, recommending that
simultaneous resection be discouraged when
the hepatectomy would be major (involving
three or more adjacent liver segments) or when
complex rectal surgery was to be performed, due
to significantly higher post-operative mortality
and morbidity [21]. Recent evidence supports
this recommendation. Schubert and co-authors
stratified synchronous hepatic and colorectal
resections, finding increased morbidity and
mortality for patients undergoing high-risk
colorectal resections and major hepatectomy
[22]. Driedger and co-authors recently pub-
lished a 17-year experience and defined major
hepatectomy as hemihepatectomy and trisec-
tionectomy, and major colectomy as left colec-
tomy with proximal diversion, total abdominal
colectomy, total abdominal proctocolectomy
and abdominoperineal resection [19]. Combin-
ing a major liver with major colorectal resection
was associated with a significant increase in
major morbidity and 90-day mortality. Also,
more than one-third of these patients were
prevented from receiving adjuvant chemother-
apy secondary to post-operative morbidity.
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investigation on surgeons’ barriers in perform-
ing simultaneous resection, with low support
for cases involving major hepatectomy [23].
Lastly, numerous prognostic indicators are
available for patients with colorectal cancer and
liver metastases, such as sidedness of primary
tumour, metastatic tumour burden (number
and size of largest lesion), and number of
involved lymph nodes of resected primary and
mutational status [24–28]. However, in the
simultaneous setting, a test of time is not pos-
sible, and unsurprisingly, a meta-analysis by
Slesser and co-authors found no difference in
overall or disease-free survival even if the
delayed surgery group had a significantly higher
proportion of major liver resections, patients
with bilobar distribution and an overall larger
metastatic tumour size [9]. Hence, until further
evidence on potential oncological benefits is
available, simultaneous surgery should be
offered to appropriate patients at specialized
centres regardless of underlying biological fea-
tures of the metastatic colorectal cancer.
In line with the above-mentioned publica-
tions and consensus statements, we believe that
simultaneous resection should be considered for
patients with localized colorectal cancer and
with limited metastatic tumour burden in the
liver, both in terms of number of lesions and
required resections and the location of the liver
metastases. We recommend avoiding resection
of more than two adjacent segments (i.e.
hemihepatectomy) for anatomical liver resec-
tions and preferably four or fewer metastases for
non-anatomical liver resections (Table 2). The
combination of ablation therapy (radiofre-
quency/microwave ablation) and hepatic resec-
tion has been proven a valid and safe modality
without increased perioperative morbidity or
mortality compared to resection alone [29]. In
order to avoid accumulation of complications
and thereby hamper the possibility of adjuvant
chemotherapy, we believe simultaneous surgery
should be restricted to patients with good per-
formance status and not in the setting of acute
bowel obstruction. Furthermore, as a higher
complication profile might be the case for
patients undergoing rectal cancer surgery,
simultaneous resection for these patients
should be considered only in selected cases. For
patients with non-resectable lung metastases
and/or extrahepatic disease, simultaneous
resection should be avoided. This is in line with
the current National Comprehensive Cancer
Network (NCCN) guidelines stating that pri-
mary tumour and resectable metastatic disease
can be resected in one operation or staged,
depending on the complexity of the hepatec-
tomy or colectomy, comorbid diseases, surgical
exposure and surgeon expertise [30].
SURGICAL TECHNIQUE
IN SIMULTANEOUS RESECTION
A laparoscopic or open approach for either part
of the procedures should be at the surgeon’s
discretion. There is reason to believe that min-
imally invasive techniques for both the liver
and the colorectal part of the procedure are
associated with beneficial short-term outcomes
[31, 32]. As for laparoscopic liver surgery, there
is evidence to support equal oncological out-
comes for laparoscopic and open colon surgery
[33, 34]. The colorectal surgery should be per-
formed by a trained colorectal surgeon and the
liver surgery by a trained hepatobiliary surgeon.
There is no evidence that higher volume per
surgical unit has a relationship with periopera-
tive outcome regarding the liver resection part
of the procedure [35], so specific volume
requirements should not be necessary. In col-
orectal cancer surgery, however, high volume
by surgeon and high volume by hospital have
been associated with better outcomes, although
the optimal threshold for a minimum number
of procedures is yet to be identified [36]. Lastly,
the optimal surgical treatment sequence in
simultaneous resection remains debatable. A
liver-first approach is reasonable, given the
possible need for a Pringle manoeuvre with a
subsequent venous stasis that could potentially
harm a bowel anastomosis. Also, a liver-first
strategy necessitates a low central venous pres-
sure during the parenchymal transection phase.
Finally, any unforeseen event during the liver
resection part (major bleed or bile leak) should
be considered as a contraindication from con-
tinuing with the bowel resection.
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LOGISTICAL CONSIDERATIONS
IN SIMULTANEOUS RESECTION
Simultaneous resection carries some logistical
challenges that have to be solved: (i) both the
colorectal and hepatobiliary surgeon need to
attend the MDT meeting, (ii) both surgeons
have to perform their part of the surgery, (iii) an
anaesthesiologist familiar with low central
venous pressure during the liver parenchymal
transection phase will have to be involved, and
(iv) both surgeons will have to do the immedi-
ate post-operative follow-up in order to catch
any sign of complications. Furthermore, ade-
quate interventional radiology resources and
inpatient facilities are mandatory in order to
avoid failure to rescue. In case patients require
neoadjuvant chemotherapy, treatment
sequence and decision on possible simultane-
ous resection should be based on response
evaluation. Whether or not neoadjuvant
chemotherapy is beneficial is beyond the scope
of this article. There is evidence that perioper-
ative chemotherapy increases disease-free sur-
vival for patients aged\75 years and with B 4
liver metastases. [37].
KNOWLEDGE GAPS
Based on the literature reviewed above, there
are still several unanswered questions concern-
ing simultaneous resection. With respect to
simultaneous resection, no randomized trials
have investigated (i) the number of liver
metastases that is considered safe to resect, (ii)
the number of liver resections or liver segments
that is considered safe to resect, (iii) the size of
the future liver remnant that is considered safe,
(iv) the timing of staged resection (liver or pri-
mary tumour first), (v) whether chemotherapy
Table 2 Proposed selection criteria in favour of simultaneous resection (green box) or staged resection (red box) of primary
colorectal cancer with liver metastases
Less than 5 liver metastases for non-anatomical liver resections  
Resections of no more than 2 adjacent liver segments for 
anatomical liver resections 
T1-T3 colorectal cancer 
Good performance status (ECOG 0-2) 
More than 4 liver metastases or resection of more than 2 adjacent 
liver segments*
T4 colorectal cancer 
Pretreatment of colon cancer with stent or acute bowel 
obstruction 
Presence of non-resectable lung metastases or extrahepatic 
disease 
ECOG ≥ 3 
Major liver with Major colorectal**
*In the case of excessive bleeding, preoperatively under-staged tumour burden, prolonged operative time, unstable patient or
any other reason to fear increased complication of either the liver-part or colorectal-part of the procedure, we recommend
avoiding simultaneous surgery
**Major liver: hemi-hepatectomy or trisectionectomy. Major colorectal: left colectomy with proximal diversion, total
abdominal colectomy, total abdominal proctocolectomy and abdominoperineal resection as defined by Driedger and co-
authors [19]
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should be administered before or after surgery,
(vi) oncological endpoints, (vii) quality of life or
(viii) health economics. The lesson learned from
current evidence is that these matters have to be
addressed in well-planned multicentre ran-
domized trials focusing on some of the above-
mentioned questions and thereby filling the
knowledge gaps in order to recommend simul-
taneous surgery to the appropriate patients.
CONCLUSION
The concept of simultaneous resection of col-
orectal cancer with limited-disease liver metas-
tases is appealing, with several potential
benefits for both patients and health care sys-
tems. Despite this, high-level evidence is lack-
ing, and an inherent reluctance exists due to the
perceived risk of accumulating complications.
We propose a pragmatic approach, consisting of
the following:
• Stringent selection criteria in order to avoid
major morbidity and mortality
• Adherence to surgical experience and prefer-
ence regarding technique
• Accepting simultaneous resections for
patients with good performance status and
a limited liver tumour burden
• Avoiding simultaneous resections when
requiring major hepatectomy and major
colorectal resection
• Discussions and strategies through a multi-
disciplinary team meeting
A liver-first strategy in the setting of simul-
taneous resection is reasonable. High-quality
trials are much needed to evaluate the role of
systemic therapy, oncological outcomes, and
both patient and health care system implica-
tions for these types of resections.
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